1st Edition
Pharmacogenetics of Breast Cancer Towards the Individualization of Therapy
Pharmacogenetics is becoming increasingly relevant in the diagnosis, treatment, and recovery of cancer patients. A major problem facing oncologists is the outstanding varied efficacy of treatment. Promising advances in pharmacogenetics have allowed the development of effective agents which will enable personalized cancer chemotherapy to become routine for the clinical practice.
Written by experts in the field and combining information that is unable to be found in a single source volume, Pharmacogenetics of Breast Cancer:
- combines a complete overview of pharmacogenetics and how it relates to breast oncology for diagnosis, treatment, and the recovery of patients using an individualized therapy model
- is the first single source reference demonstrating the application of pharmacogenetics in the care of breast cancer patients
- enables physicians a coherent interpretation of the emerging science of pharmacogenetics, aiding them to incorporate individual therapies in their own practice
- gives practical guidance on various forms of specimen collection, tissue selection, and handling procedures
Biography
BRIAN LEYLAND-JONES is Associate Vice President and Director, Emory Winship Cancer Institute, Emory University, Atlanta, Georgia. Dr. Leyland-Jones’ main research interests are pharmacodynamics, pharmacokinetics, and pharmacogenetics in oncological clinical trials; translation of preclinical models into the clinic; biomarker endpoints in Phase I/II clinical trials; and screening and mechanistic studies of novel targeted and chemotherapeutic anti-cancer agents. He has authored more than 125 peer-reviewed articles and book contributions, 150 abstracts, and 29 patents.